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Abstract: Vitamin D deficiency is associated with increased arterial stiffness. However, the
mechanisms underlying this association have not been clarified. The aim was to investigate
whether changes in autonomic nervous system activity could underlie an association between
25 hydroxy vitamin D and arterial stiffness. A total of 49 subjects (age = 60 ± 8 years,
body mass index = 26.7 ± 4.6 kg/m2, 25 hydroxy vitamin D = 69 ± 22 nmol/L) underwent
measurements of pulse wave velocity (PWV) and augmentation index (AIx), spontaneous baroreflex
sensitivity, plasma metanephrines and 25 hydroxy vitamin D. Subjects with 25 hydroxy vitamin
D ≤ 50 nmol/L were restudied after 200,000 International Units 25 hydroxy vitamin D. Plasma
metanephrine was positively associated with AIx (p = 0.02) independent of age, sex, smoking
and cholesterol and negatively associated with 25 hydroxy vitamin D (p = 0.002) independent
of age, sex and season. In contrast, there was no association between baroreflex sensitivity and
25 hydroxy vitamin D (p = 0.54). Treatment with vitamin D increased 25 hydroxy vitamin D from
43 ± 5 to 96 ± 24 nmol/L (p < 0.0001) but there was no significant change in plasma metanephrine
(115 ± 25 vs. 99 ± 39 pmol/L, p = 0.12). We conclude that as plasma metanephrine was negatively
associated with 25 hydroxy vitamin D and positively with AIx, it could mediate an association
between these two variables. This hypothesis should be tested in larger interventional studies.
Keywords: 25 hydroxy vitamin D; pulse wave velocity; augmentation index; baroreflex
sensitivity; metanephrine
1. Introduction
Vitamin D is a steroid hormone that has clinical effects beyond its established role in skeletal
health. Low concentrations of 25-hydroxy vitamin D and 1,25-dihydroxy vitamin D are associated
with increased cardiovascular events and mortality in observational studies [1–3]. However, it is
unclear whether vitamin D deficiency increases cardiovascular mortality directly or is a biomarker for
another medical condition or pathophysiological pathway that alters cardiovascular risk. There are
no sufficiently powered interventional studies to determine an effect of vitamin D treatment on
cardiovascular events. Lacking this data, investigation of mechanisms by which vitamin D deficiency
could affect cardiovascular physiology may aid interpretation of the relationship between vitamin D
and cardiovascular health.
Increased arterial stiffness and arterial wave reflection, an indirect marker of arterial stiffness, have
been proposed as mechanisms linking vitamin D deficiency and cardiovascular events. These measures,
considered major determinants of systolic blood pressure and pulse pressure, and consequently
cardiovascular risk [4,5], have been negatively associated with vitamin D concentration [6–8]. Arterial
stiffness is increased by arterial wall pathology such as atherosclerosis and calcification and is
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also tonically regulated by endothelial nitric oxide production [9]. Vitamin D deficiency has been
associated with these structural and functional vascular disorders in some studies [6,10,11], but not
in others [12]. Therefore, further investigation of mechanisms linking serum vitamin D and arterial
stiffness is warranted.
The autonomic nervous system is another major regulator of arterial stiffness [13] and autonomic
dysfunction is associated with an increased risk of cardiovascular mortality [14]. However, few studies
have investigated the relationship between vitamin D and autonomic nervous system activity.
Low concentrations of 1,25 dihydroxy vitamin D, but not 25 hydroxy vitamin D, were associated
with autonomic dysfunction in response to angiotensin II challenge [15]. However, 25 hydroxy vitamin
D treatment attenuated an unfavourable autonomic nervous system response to angiotensin II [16].
In contrast, an in vitro study reported 1,25-dihydroxyvitamin D increased tyrosine hydroxylase mRNA,
suggesting that vitamin D might stimulate the rate limiting step in catecholamine biosynthesis [17].
With these conflicting results, there is interest in further investigation into the relationship between
vitamin D and autonomic nervous system activity [18].
Increased renin secretion has also been proposed as a mechanism linking vitamin D deficiency and
cardiovascular events. In animal models, vitamin D deficiency has been associated with increased renin
secretion [19]. As the sympathetic nervous system stimulates renin secretion, increased sympathetic
nervous system activity could mediate an association between vitamin D deficiency and renin secretion.
The aim of this study was to investigate whether changes in autonomic nervous system activity
could underlie an association between serum vitamin D and arterial stiffness. We hypothesized that
autonomic dysfunction could mediate an association between vitamin D and arterial stiffness, either
directly or indirectly via an effect on the renin-angiotensin-aldosterone system.
2. Methods
2.1. Subjects
We recruited 49 subjects aged 30–80 years both from the Metabolic Bone Clinic, Repatriation
General Hospital and from the general community by advertisement in local newspapers. Subjects
were excluded if they had taken calcium or vitamin D supplements in the prior 3 months or if
they were taking a beta blocker medication, had diabetes mellitus, atrial fibrillation or Raynaud’s
phenomenon, were pregnant or were unable to provide written informed consent. Two subjects were
excluded from the statistical analyses; one because their blood results revealed previously undiagnosed
hypoparathyroidism and one because limited venous access precluded measurement of serum vitamin
D. Therefore, 47 subjects were included in the final analysis of most variables. Only 43 subjects had
sufficient plasma stored for metanephrine analysis.
2.2. Study Design
These studies were undertaken within the Endocrine Research Unit, Repatriation General
Hospital, Adelaide, Australia. The study was approved by the Research and Ethics Committee,
Repatriation General Hospital (Number 42/07, approved 27 July 2009) and all subjects provided
written informed consent. Subjects attended the Endocrine Research Unit at 08.30 a.m. after an
overnight fast. After resting for 30 min, pulse wave analysis, pulse wave velocity (PWV) and an
assessment of autonomic nervous system activity were performed and then a blood sample was
collected. Subjects with a serum 25 hydroxy vitamin D concentration ≤50 nmol/L were restudied
4–6 weeks after administration of two oral doses of 100,000 International Units 25 hydroxy vitamin D
administered two weeks apart (Biological Therapies, South Australia, Australia).
2.3. Pulse Wave Analysis
Pulse wave analysis was performed using a SphygmoCor device (AtCor Medical, West Ryde,
NSW, Australia) and a high-fidelity micromanometer (SPC-301, Millar Instruments, Houston, TX,
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USA) as previously described [20,21]. One investigator (BLM) performed all measurements. The radial
pulse waveform was recorded and central aortic pressure derived using an automated generalized
transfer function. The augmentation index (AIx) was calculated as the increment in pressure from the
first shoulder in the ascending aortic pressure wave to the peak of this wave. The day-to-day intraclass
correlation for AIx for this operator is 0.82. To correct for differences in pulse rate, AIx results were
normalized to a heart rate of 75 beats/min. The quality control indices within the SphygmoCor device
software were used to verify the quality of recorded waveforms. If indices were outside acceptable
limits the waveform was discarded and the measurement repeated. Results for AIx are at an average
of five consecutive recordings.
2.4. Pulse Wave Velocity
PWV was performed by combining pulse wave analysis at the carotid and femoral arteries with
simultaneous electrocardiograph recording [20]. PWV is calculated by measuring the difference in time
the pulse waveform takes to reach the carotid and femoral arteries. Reported results are the average of
six consecutive recordings. The average day-to-day coefficient of variation (CV) for PWV is 7.6%.
2.5. Autonomic Nervous System Activity
Plasma normetanephrine and metanephrine were measured after solid-phase extraction from
plasma using a5500 tandem mass spectrometer (AB Sciex Australia Pty Ltd., Mount Waverley, VIC,
Australia) [22]. The between-run CV of the method is <6% for normetanephrine and metanephrine.
Spontaneous baroreflex sensitivity quantified using the sequence method and heart rate spectral
parameters were measured using a Taskforce Haemodynamic Monitor 3040i (CNSystems, Graz,
Austria) [23]. Four electrodes were placed on the subject’s anterior chest for measurement of heart rate
and a “flying V” finger cuff on the subject’s hand to measure beat-by-beat arterial pressure, allowing
simultaneous analysis of heart rate and blood pressure variability. Following resting supine for 10 min,
recordings were performed for 20 min.
2.6. Other Laboratory Analysis
25 hydroxy vitamin D and 1,25 dihydroxy vitamin D were measured by chemiluminescent
assays (IDS-iSYS, IDS Ltd., Boldon, UK) with CVs of 7%–11% and 10%–18% respectively. Renin and
aldosterone were measured by chemiluminescent assays (Diasorin, Stillwater, MN, USA) with CVs of
<10% and <5% respectively. PTH was measured by electrochemiluminescent immunoassay (Roche
Diagnostics GmbH, Mannheim, Germany) with CV of <4%. Fasting lipid profiles were measured by
enzymatic colorimetry (Roche Modular P Unit; Roche Diagnostics GmbH, Mannheim, Germany).
2.7. Statistical Analysis
Data were analysed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA) with p < 0.05
considered statistically significant. Results are presented as mean ± standard deviation if normally
distributed and median (interquartile range) if the distribution was not normal. First, multivariable
linear regression analyses were performed to assess the relationship between measures of autonomic
nervous system activity and arterial stiffness with age, sex, smoking status and serum cholesterol
covariates in these analyses. Variables that were not normally distributed were log-transformed prior
to these analyses to achieve a normal distribution. Next, multivariable linear regression analyses
assessed the relationship between measures of autonomic nervous system activity and 25 hydroxy
vitamin D, 1,25 dihydroxy vitamin D and PTH with age, sex, and season covariates in these analyses.
A subgroup analysis was then performed on the 37 subjects who were not taking anti-hypertensive
therapy to assess whether measures of autonomic nervous system activity that correlated with vitamin
D were correlated with serum renin or aldosterone. Finally, changes in variables after vitamin D
treatment were assessed using paired t-tests for normally distributed data and a Wilcoxon Signed
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Rank test for data where the distribution was not normal. The primary endpoints were the relationship
between 25 hydroxy vitamin D and PWV and baroreflex sensitivity.
3. Results
3.1. Subject Characteristics
Thirty-five of the 47 subjects were female. The subjects’ mean age was 60 ± 8 years, weight was
74 ± 15 kg, height was 1.66 ± 0.09 m, body mass index was 26.7 ± 4.6 kg/m2 and waist circumference
was 89 ± 13 cm. Only one subject had a history of cardiovascular or cerebrovascular disease,
five subjects were current smokers and 10 subjects were treated for hypertension. The subjects’
25 hydroxy vitamin D was 69 ± 22 nmol/L, 1,25 dihydroxy vitamin D was 102 (85–129) pmol/L,
normetanephrine was 340 (260–450) pmol/L and metanephrine was 98 ± 29 pmol/L.
3.2. Associations between Arterial Stiffness and Autonomic Nervous System Activity
Baroreflex sensitivity and high frequency heart rate variability were negatively associated with
PWV, independent of age, sex, smoking status and serum cholesterol (Table 1). Low frequency heart rate
variability, LF:HF ratio, plasma normetanephrine and plasma metanephrine were not independently
associated with PWV. Plasma metanephrine was positively associated with AIx, independent of age,
sex, smoking status and serum cholesterol (Table 1). Baroreflex sensitivity, low frequency heart rate
variability, high frequency heart rate variability, LF:HF ratio and plasma normetanephrine were not
independently associated with AIx.
Table 1. Multiple regression analyses of the relationship between measures of autonomic nervous
system activity and arterial stiffness in 47 subjects.
Pulse Wave Velocity * Augmentation Index
β Coefficient p Value β Coefficient p Value
Heart rate variability
Baroreflex sensitivity * −0.30 0.04 +0.01 0.93
Low Frequency (LF) band * −0.26 0.06 +0.10 0.44
High Frequency (HF) band * −0.33 0.02 +0.10 0.47
LF:HF * +0.04 0.14 +0.05 0.72
Plasma catecholamine metabolites
Normetanephrine *,# +0.09 0.97 +0.10 0.48
Metanephrine # +0.00 0.46 +0.34 0.02
* Variable log-transformed before multiple regression analysis; # 43 subjects included in analysis; p values are
independent of age, sex, smoking status and serum cholesterol.
3.3. Associations between Autonomic Nervous System Activity and Vitamin D/PTH
Figure 1 depicts the univariable relationship between serum 25 hydroxy vitamin D concentration
and plasma metanephrine. Plasma metanephrine was negatively associated with serum 25 hydroxy
vitamin D concentration, independent of age, sex and season (Table 2). Baroreflex sensitivity,
low frequency heart rate variability, high frequency heart rate variability, LF:HF ratio and plasma
normetanephrine were not independently associated with serum 25 hydroxy vitamin D concentration
(Table 2). The negative correlation between 25 hydroxy vitamin D and AIx, albeit similar to that
reported in previous studies [6], was not statistically significant (r = −0.24, p = 0.10). 1,25 dihydroxy
vitamin D and PTH were not significantly associated with measures of autonomic nervous system
activity (Table 2).
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Metanephrine #  −0.55  0.002 −0.04  0.83  +0.21  0.28 
* Variable  log‐transformed before multiple  regression  analysis. PTH  = parathyroid hormone;  #  43 
subjects included in analysis; p values are independent of age, sex and season. 
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Table 3. Effect of the administration of 200,000 International Units vitamin D on the renin angiotensin
system and cardiovascular function in 12 subjects.
Before After p Value
25 hydroxy vitamin D (nmol/L) 43 ± 5 96 ± 24 <0.0001
1,25 dihydroxy vitamin D (pmol/L) 113 ± 39 146 ± 67 0.02
Renin (µIU/mL) 7.5 (3.1–15.5) 8.1 (4.4–12.7) 0.44
Aldosterone (pmol/L) 133 ± 89 188 ± 198 0.15
Pulse (beats/min) 65 ± 6 68 ± 10 0.053
Systolic BP (mmHg) 132 ± 22 131 ± 18 0.91
Diastolic BP (mmHg) 76 ± 10 76 ± 10 0.91
Pulse wave velocity (m/s) 8.3 (6.6–9.3) 8.6 (6.5–10.5) 0.37
Augmentation index (%) 28 ± 5 26 ± 7 0.21
Baroreceptor sensitivity (m/s) 13.6 (8.8–17.0) 14.9 (8.8–18.9) 0.64
Low Frequency band 202 (112–661) 297 (101–517) 0.64
High Frequency band 216 (95–634) 301 (152–786) 0.29
LF:HF 0.8 (0.6–1.0) 0.8 (0.6–1.0) 0.72
Normetanephrine (pmol/L) 300 (260–530) 300 (200–390) 0.45
Metanephrine (pmol/L) 115 ± 25 99 ± 39 0.12
Values represent mean ± standard deviation or median (interquartile range). BP = blood pressure.
4. Discussion
In this study we have investigated whether changes in autonomic nervous system activity could
underlie an association between serum vitamin D and arterial stiffness. There was an independent
association between several measures of autonomic nervous system activity and arterial stiffness.
However, only plasma metanephrine was associated with 25 hydroxy vitamin D. This suggests that
vitamin D could modulate catecholamine synthesis and/or secretion from the adrenal medulla, which
could contribute to the relationship between serum vitamin D and cardiovascular risk.
We found that different measures of autonomic nervous system activity were associated with
PWV and AIx. There are differences in the physiologic principles underlying measures of both
arterial stiffness and autonomic nervous system activity that are likely to explain any discordance.
Carotid-femoral PWV is considered the gold standard measure of arterial stiffness as it directly reflects
arterial stiffness in the aorta [24]. However, AIx is an indirect marker of arterial stiffness that is also
influenced by other variables, in particular the pattern and duration of left ventricular ejection [24].
Quantification of baroreflex sensitivity by the sequence method and heart rate variability by spectral
analysis predominantly reflect parasympathetic nervous system activity [25]. Plasma normetanephrine
is produced in both the sympathetic nervous system and adrenal medulla [26]. In contrast, plasma
metanephrine is mainly a measure of catecholamine synthesis in the adrenal medulla as over 90% of
circulating plasma metanephrine is produced in the adrenal glands [26].
PVW was independently associated with baroreflex sensitivity and high frequency heart rate
variability. As these are both measures of parasympathetic nervous system activity, our data suggest
that the parasympathetic nervous system is an important regulator of arterial stiffness. AIx was
not associated with baroreflex sensitivity or heart rate spectral parameters, but was independently
associated with plasma metanephrine. The lack of association between PWV and plasma metanephrine
suggests that the latter does not influence arterial stiffness per se. Therefore, the association between
AIx and plasma metanephrine could be explained by adrenaline and its metabolites stimulating cardiac
output, which would affect AIx, but not PWV.
In this study, 25 hydroxy vitamin D was negatively correlated with plasma metanephrine
(Figure 1). Furthermore, the association was stronger when the relationship was corrected for age, sex
and season. As plasma metanephrine is mainly derived from the adrenal glands [26], we propose that
low concentrations of 25 hydroxy vitamin D could stimulate catecholamine production in the adrenal
medulla. It has been postulated that vitamin D could cross the blood brain barrier and modulate
autonomic nervous system activity centrally [18]. However, while we cannot exclude an effect of
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vitamin D on central nervous system activity, our study suggests that vitamin D status is predominantly
associated with adrenal medullary function.
Plasma noradrenaline and adrenaline concentrations are higher in winter than in summer [27].
Plasma normetanephrine follows a similar seasonal pattern [28]. The seasonal variability in plasma
metanephrine concentration is less marked, but metanephrine concentrations are higher in spring than
in autumn [28]. Stimulation of the sympathetic nervous system by cold temperature has been proposed
as a mechanism to explain these findings. However, the negative association between 25 hydroxy
vitamin D and plasma metanephrine raises the possibility that low vitamin D concentrations could
contribute to seasonal changes in adrenaline and metanephrine. The lack of association between
25 hydroxy vitamin D and normetanephrine suggests vitamin D status is unlikely to underlie seasonal
variation in plasma normetanephrine.
We recognize that an association between 25 hydroxy vitamin D and plasma metanephrine
does not demonstrate cause and effect. Although our subjects did not have an obvious intercurrent
illness, a low 25 hydroxy vitamin D could be a surrogate for another variable that stimulates
catecholamine secretion. In our interventional study, plasma metanephrine fell by 14% after
vitamin D supplementation, however this change was not statistically significant. While this could
represent a type 2 error, there was an increase in heart rate following vitamin D replacement that
approached statistical significance and no change in systolic or diastolic blood pressure. Furthermore,
a meta-analysis reported no effect of vitamin D supplementation on systolic or diastolic blood
pressure [29]. These findings are not consistent with the hypothesis that replenishing vitamin D
stores reduces catecholamine secretion from the adrenal medulla. However, our interventional study
was small and the effect of vitamin D on blood pressure could be multifactorial. Our cross-sectional
study suggests a need for larger studies investigating the effect of vitamin D replacement on adrenal
medullary function.
25 hydroxy vitamin D was not significantly associated with baroreflex sensitivity or heart rate
spectral parameters, suggesting it does not alter basal parasympathetic nervous system activity.
A previous study reported that vitamin D does affect parasympathetic nervous system activity [16].
However, in that study, the effect of vitamin D on parasympathetic nervous system activity became
apparent during an angiotensin II challenge [16]. While we may have missed this effect, we did
investigate subjects under conditions they will experience during their day-to-day lives.
There were no significant associations between 1,25 dihydroxy vitamin D or PTH and measures
of autonomic nervous system activity. 1,25 dihydroxy vitamin D was reported to stimulate tyrosine
hydroxylase activity in vitro [17]. In contrast, we did not find a significant association between
1,25 dihydroxy vitamin D and plasma metanephrine in vivo. Previous studies have suggested that
PTH, which is affected by vitamin D status, may directly regulate arterial stiffness [30]. However, there
were no significant associations between PTH and measures of autonomic nervous system activity,
suggesting that any effect of PTH on arterial stiffness is not mediated by the autonomic nervous system.
Stimulation of the renin-angiotensin-aldosterone system has been proposed as a mechanism
linking vitamin D deficiency and cardiovascular disease [19]. As the sympathetic nervous system
stimulates renin secretion, we hypothesized that this relationship might be indirect and mediated
by changes in autonomic nervous system activity. However, there was no correlation between
plasma metanephrine—the only measure of autonomic nervous system activity associated with
25 hydroxy vitamin D concentration—and renin or aldosterone. As such, we did not find evidence
that a relationship between vitamin D deficiency and the renin-angiotensin-aldosterone system is
modulated by the autonomic nervous system.
We acknowledge that our study has limitations. Firstly, the cross-sectional study may show an
association but does not establish cause and effect. However, it does provide insight into appropriate
endpoints for future interventional studies, in particular adrenal catecholamine secretion. Secondly,
the sample size was relatively small. Nevertheless, the cross-sectional study sample size was sufficient
to show relationships between autonomic nervous system activity and arterial stiffness that were
Nutrients 2016, 8, 565 8 of 10
independent of other variables. Thirdly, there are more refined techniques to measure sympathetic
nervous system activity available than plasma metanephrines, which additionally have a shorter
half-life than that of 25 hydroxy vitamin D. However, plasma samples were collected after fasting
and supine, conditions shown to reduce variability in plasma metanephrines [31]. Fourthly, we
did not measure serum oestradiol, and variability throughout the menstrual cycle could potentially
influence vascular function. Nevertheless, this is unlikely to have had a major effect on results as only
two subjects were female and aged ≤50 years. Finally, we did not measure fat mass, which may have
influenced 25 hydroxy vitamin D concentration.
In summary, baroreflex sensitivity, high frequency heart rate variability and plasma metanephrine
were associated with measures of arterial stiffness. However, only plasma metanephrine was
significantly associated with 25 hydroxy vitamin D. This suggests that plasma metanephrine could
mediate an association between 25 hydroxy vitamin D and AIx. Future larger interventional studies
should investigate whether vitamin D treatment reduces catecholamine secretion from the adrenal
medulla and whether this reduces arterial stiffness and other surrogate markers of cardiovascular risk.
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